Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Giagounidis, Aristoteles, Fenaux, Pierre, Mufti, Ghulam J., Muus, Petra, Platzbecker, Uwe, Sanz, Guillermo, Cripe, Larry, Von Lilienfeld-Toal, Marie, Wells, Richard A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer-Verlag 2008
Schlagworte:
Review Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275303/
https://ncbi.nlm.nih.gov/pubmed/18265982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-008-0449-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge